Vanadium, being a trace transition metal, possesses potential biological, pharmacological, and physicochemical properties. Over the past few decades, there has been a significant surge in interest regarding the chemistry of polyoxidovanadates. This increased interest primarily stems from the utilization of vanadium in the bioinorganic field, specifically for the treatment of diabetes [1]. Several studies have highlighted the association between diabetes and cancer, with shared risk factors such as obesity, sedentary lifestyle, and aging [2,3]. The insulin/insulin-like growth factor (IGF) axis, hyperglycemia, inflammatory cytokines, and sex hormones have been identified as key factors contributing to the development and progression of cancer in individuals with diabetes [4,6]. Additionally, antidiabetic drugs, such as sulfonylureas, biguanides, and thiazolidinediones, have shown beneficial effects in the management of cancer, further emphasizing the metabolic links between the two disorders [7]. Furthermore, both decavanadate and polyoxidovanadates hold promise as therapeutic agents [8]. Numerous studies have demonstrated that the in-vitro anticancer activity might be attributed to the inhibitory effects exerted on specific enzymes involved in tumor proliferation [9]. Over the past few years, numerous research articles have been released that establish the anti-tumor capabilities of decavanadate compounds [[10], [11], [12]]. More recently, two synthesized decavanadate compounds were examined for their anti-tumor effects in laboratory settings using human lung carcinoma cells (A549) and murine leukemia cells (P388). The results were remarkable, demonstrating a captivating inhibitory influence [13]. Both compounds demonstrated decreased inhibition compared to cisplatin compounds. However, the decavanadate compound, which possessed a greater degree of lipophilicity, consequently bolstered its ability to penetrate the lipid bilayer of the cell membrane, resulting in heightened inhibitory activity [14]. Other decavanadate compounds also exhibited an apoptotic mode of cell death, yet displayed inferior activity when compared to platinum compounds [15]. It is crucial to note that the significant negative charge of decavanadate enables these units to engage with various molecules, including proteins or lipid structures. This interaction disrupts numerous biological processes, such as muscle contraction, oxidative stress markers, or necrosis [16]. Recently, researchers have shown interest in the structures formed by decavanadate and ligands containing nitrogenous groups. In fact, organic ligands can improve the bioactivity and biospecificity of decavanadate compounds, making them more effective in cancer treatment [17]. By grafting organic ligands onto decavanadate clusters, the resulting compounds can easily bind to cell membranes and be taken up by cancer cells, leading to increased antitumor activity [18]. Additionally, the use of organic ligands can help stabilize decavanadate compounds under biological conditions, allowing for their successful administration via intratumoral injections [19].The combination of decavanadate with organic ligands also opens up the possibility of targeting specific RNA molecules, further enhancing the potential anticancer activity of these compounds [20]. Taking into account these findings, the synthesis of new decavanadate compounds using methenamine and 4-dimethylaminopyridinium as ligands capable of interacting with the decavanadate anion and studying their anticancer activity has been focused on.